Document Detail

Surgical Outcomes in Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombosis.
MedLine Citation:
PMID:  24132826     Owner:  NLM     Status:  Publisher    
BACKGROUND: Different approaches to surgical treatment of portal vein tumor thrombosis (PVTT) have been advocated. This study investigated the outcomes of different surgical approaches in hepatocellular carcinoma (HCC) patients with PVTT.
METHODS: We reviewed prospectively collected data for all patients who underwent hepatectomy for HCC at our hospital between December 1989 and December 2010. Patients were excluded from analysis if they had extrahepatic disease, PVTT reaching the level of the superior mesenteric vein, or hepatectomy with a positive resection margin. The remaining patients were divided into three groups for comparison: group 1, with ipsilateral PVTT resected in a hepatectomy; group 2, with PVTT extending to or beyond the portal vein bifurcation, treated by en bloc resection followed by portal vein reconstruction; group 3, with PVTT extending to or beyond the portal vein bifurcation, treated by thrombectomy.
RESULTS: A total of 88 patients, with a median age of 54 years, were included in the analysis. Group 2 patients were younger, with a median age of 43.5 years versus 57 in group 1 and 49 in group 3 (p = 0.017). Group 1 patients had higher preoperative serum alpha-fetoprotein levels, with a median of 8,493 ng/mL versus 63.25 in group 2 and 355 in group 3 (p = 0.004), and shorter operation time, with a median of 467.5 min versus 663.5 in group 2 and 753 in group 3 (p = 0.018). No patient had thrombus in the main portal vein. Two (2.8 %) hospital deaths occurred in group 1 and one (10 %) in group 2, but none in group 3 (p = 0.440). The rates of complication in groups 1, 2, and 3 were 31.9, 50.0, and 71.4 %, respectively (p = 0.079). The median overall survival durations were 10.91, 9.4, and 8.58 months, respectively (p = 0.962), and the median disease-free survival durations were 4.21, 3.78, and 1.51 months, respectively (p = 0.363). The groups also had similar patterns of disease recurrence (intrahepatic: 33.8 vs. 28.6 vs. 40.0 %; extrahepatic: 16.9 vs. 14.3 vs. 0 %; both: 28.2 vs. 42.9 vs. 40.0 %; no recurrence: 21.1 vs. 14.3 vs. 20.0 %; p = 0.836).
CONCLUSIONS: The three approaches have similar outcomes in terms of survival, complication, and recurrence. Effective adjuvant treatments need to be developed to counteract the high incidence of recurrence.
Kenneth S H Chok; Tan To Cheung; See Ching Chan; Ronnie T P Poon; Sheung Tat Fan; Chung Mau Lo
Related Documents :
18561116 - Treatment of tinnitus with a customized acoustic neural stimulus: a controlled clinical...
24144426 - An intact parathyroid hormone-based protocol for the prevention and treatment of sympto...
23925736 - Mycophenolate versus cyclophosphamide for progressive interstitial lung disease associa...
24581216 - Comparison of ho:yag laser and pneumatic lithotripsy in the treatment of impacted urete...
19533196 - Grice arthrodesis in the treatment of valgus feet in children with myelomeningocele: a ...
6825866 - Diagnosis and treatment of intrauterine adhesions by microhysteroscopy.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-10-17
Journal Detail:
Title:  World journal of surgery     Volume:  -     ISSN:  1432-2323     ISO Abbreviation:  World J Surg     Publication Date:  2013 Oct 
Date Detail:
Created Date:  2013-10-17     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7704052     Medline TA:  World J Surg     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Department of Surgery, The University of Hong Kong, 102 Pok Fu Lam Road, Hong Kong, China,
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Stroke Volume Response to Liver Graft Reperfusion Stress in Cirrhotic Patients.
Next Document:  Outcome After Curative Surgery for Gastric Cancer Patients with Type 2 Diabetes.